Novel peptide-saccharide conjugates for prevention of intestinal infection

用于预防肠道感染的新型肽-糖缀合物

• 批准号: 14560092
• 负责人: HATTORI Makoto
• 金额: $ 2.18万
• 依托单位: Tokyo University Agriculture And Technology
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14560092/
• 关键词: intestinal infection; prevention; glycopeptide; glycomacropeptide; ovomucin

Preventive effects of glycomacropeptide (GMP) and ovomucin glycopeptide (OGP) against intestinal infection were investigated and the conjugates of GMP with xylooligosaccharide (XOS) and carboxymethyldextran (CMD) were prepared by the Maillard reaction to enhance the effect of GMP. Binding ability of GMP to intestinal pathogenic bacteria was evaluated by ELISA with biotinylated bacteria. GMP showed binding ability to Salmonella enteritidis (S.enteritidis) and enterohaemorrhic Escherichia coli O157:H7 (EHEC O157). OGP showed binding ability to EHEC O157. These binding abilities markedly decreased by sialydase treatment and were completely eliminated by penodate oxidation. These results indicated that carbohydrate moieties such as sialic acid in GMP and OGP are involved in binding to these bacteria. The effect of GMP on the adhesion and invasion of pathogenic bacteria to Caco-2 cells was also investigated. GMP was not potent inhibitor to adhesion and invasion of Salmonella infection. However, GMP-XOS and GMP-CMD significantly suppressed IL-8 production which was the index of infection. Our results indicate that GMP and OGP are promising as the agent to prevent intestinal infection.

研究了糖氨基肽（GMP）和卵瘤糖肽（OGP）对肠道感染的预防作用，并通过Maillard反应增强GMP效应的Maillard反应来制备GMP与Xyloolooligosacachire（XOS）和羧甲基二糖（XOS）和羧甲基二糖（CMD）的结合作用。通过生物素化细菌ELISA评估了GMP与肠道致病细菌的结合能力。 GMP表现出与沙门氏菌（S. enteritidis）和肠胃外大肠杆菌O157：H7（EHEC O157）的结合能力。 OGP具有与EHEC O157的结合能力。这些结合能力通过辅助酶处理明显降低，并通过阴茎氧化完全消除。这些结果表明，GMP和OGP中唾液酸等碳水化合物部分与这些细菌的结合有关。还研究了GMP对致病细菌对CACO-2细胞的粘附和侵袭的影响。 GMP不是对沙门氏菌感染的粘附和侵袭的有效抑制剂。但是，GMP-XOS和GMP-CMD显着抑制了IL-8的产生，这是感染指数。我们的结果表明，GMP和OGP作为预防肠道感染的药物有望。